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ADVANCING FLUID MANAGEMENT IN PERITONEAL DIALYSIS
Introduction
Optimal fluid management is recognized as a crucial tions. A new osmotic agent (icodextrin) consisting of a
determinant of survival in patients on renal replacement family of glucose polymers has been introduced to satisfy
therapy. This realization, however, and the resultant nec- the unmet clinical need. Moberly et al report on a new
essary changes in clinical approaches have not been es- study of the kinetic profile of icodextrin that underlies
tablished in normative ways in clinical practice guidelines. its unique mechanism of action and its clinical success.
Further, advances in the clinical tools for fluid removal They identify its pathways of removal from the perito-
in patients with end-stage renal disease (ESRD) have neal cavity and from the circulation after absorption.
occurred at a pace that may have outdistanced current The predominantly convective pathway of removal from
clinical behavior. It is the aim of the present Supplement the peritoneal cavity explains its high residence time dur-
issue to Kidney International to fill these gaps by offering ing a long dwell and hence the reason for its sustained
clinical approaches and tools to advance fluid manage- effect to promote ultrafiltration.
ment in patients on peritoneal dialysis. The absence of free glucose from the icodextrin-based
The centrality of fluid management as a potential mod- dialysis solution has several implications at the level of
ifier of outcomes is stressed by the overview of the impact the peritoneal membrane. These are reviewed in the
of congestive heart failure on outcomes in patients with article by Cooker and her colleagues. Lower levels of
ESRD presented by Collins. The current status of this pop- glucose degradation products and lower osmotic stress
ulation harkens to a dark description by Dante (“In the are a few of the changes that may ultimately translate
hallways of hell I saw people who were not dead and were into enhanced peritoneal membrane viability during
not alive”). Collins, however, highlights the areas of poten- long-term peritoneal dialysis.
tial improvement in the delivery of care to this population, Icodextrin-based solutions have been the subject of
particularly those pertaining to cardiovascular morbidity. intensive clinical investigation since their introduction
This is a sobering review of the status of clinical care in Europe more than a decade ago. Wolfson et al have
meant to identify areas that need focused interventions. analyzed this trial database in a uniform and rigorous
Guidelines on fluid management in ESRD are notori- approach, and offer insights into the efficacy and safety
ously absent from the roster of clinical practice require- of icodextrin that are very valuable in guiding clinical
ments issued by many professional societies. Abu-Alfa use of this new solution.
et al attempt to bridge this gap by formulating such guide- Among patients on peritoneal dialysis, those with a
lines and presenting both the rationale for their adoption fast glucose transport appear to exhibit the most the
as well as the practical processes that will facilitate their inadequacies of glucose-based solutions under the condi-
implementation. The latter are firmly based on the knowl- tions of a long dwell. A fast glucose transport by the
edge of peritoneal physiology of ultrafiltration and its peritoneal membrane leads to a rapid dissipation of the
determinants, a topic that is summarized by Mujais and osmotic gradient, a major handicap of small molecular
Vonesh. Both of these articles identify the long dwell in weight osmotic agents. A reversible type of fast glucose
peritoneal dialysis as the area of greatest risk for therapeu- transport occurs during peritoneal inflammation, and a
tic failure and suggest that negative (or even neutral) net potentially reversible type occurs during long-term peri-
ultrafiltration be considered for corrective intervention. toneal dialysis, particularly if hypertonic glucose solu-
The small molecular weight of glucose and its absorp- tions have been used liberally for fluid control. Krediet
tion pathways from the peritoneal cavity make it unsuit- and Mujais review the mechanisms underlying the im-
able for maintenance of ultrafiltration during the long paired ultrafiltration capacity under conditions of fast
dwell unless very high concentrations are used. These peritoneal glucose transport and discuss the particular
high concentrations have been implicated in a series of usefulness of icodextrin-based solutions in this setting.
local (intraperitoneal), systemic and clinical nefarious The use of a new class of osmotic agents in peritoneal
consequences. A high price is paid at the level of perito-
dialysis solutions has several metabolic implications. Go-
neal viability, systemic carbohydrate load, and patient
kal et al review these under two headings: the ameliorationdiscomfort for the use of very hypertonic glucose solu-
of the metabolic consequences of glucose-based solutions
by their partial replacement with icodextrin, and the labo-
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compartmentalization of metabolic pathways gives ico- PD is also an opportunity to revisit the clinical needs
and requirements in the field and the novel conceptualdextrin its unique properties. Within the peritoneum in
and practical aspects presented by the new agents. Pec-humans, there is minimal metabolism of glucose poly-
oits-Filho and his colleagues undertake such an explora-mers. In the intravascular compartment, the major meta-
tions of current and future themes, and highlight howbolic products are small oligosaccharides such as maltose.
an alternate mechanism of action for ultrafiltration alsoThe final metabolic step is predominantly intracellular
translates into differential solute clearances, particularlywhere glucose is released. While icodextrin is fully and
in the middle molecular weight range.completely metabolizable to glucose, the compartmen-
This compendium of articles is consonant with the cur-talization of the metabolic pathways explains the unique
rent emphasis in the renal community on improvementability of a glucose polymer osmotic agent to have meta-
of outcomes of patients with end-stage renal disease. We
bolic effects distinct from glucose. hope that clinicians find the information and insights
The use of icodextrin-based solutions for the long offered here useful and meaningful for their patients. It
dwell results in clinical benefits and has the potential to has been 25 years since peritoneal dialysis became a
alleviate discomfort issues and complexities in therapeu- standard therapy for ESRD. The work of dialysis pio-
tic regimen. In automated PD for example, mid-day neers has been done against much uncertainty, uncharted
drains or exchanges are frequently used for ultrafiltration territory, and myriad obstacles, yet has been crowned
enhancement rather than for clearance needs. In such by success. The task for the future has been best summa-
rized by Nietzsche: “One repays a teacher badly if onecases, the greater efficacy of icodextrin-based solutions
remains a pupil.”also may translate to lifestyle advantages for patients on
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